Selected research
Industry Research
Metachromatic Leukodystrophy (MLD) Treatment Industry Research Report 2026
Market perspective
The global Metachromatic Leukodystrophy (MLD) Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Metachromatic Leukodystrophy (MLD) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Metachromatic Leukodystrophy (MLD) Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Metachromatic Leukodystrophy (MLD) Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Metachromatic Leukodystrophy (MLD) Treatment include Takeda, GlaxoSmithKline Plc, RegenxBio Inc, Recursion Pharmaceuticals Inc and ArmaGen Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Metachromatic Leukodystrophy (MLD) Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Metachromatic Leukodystrophy (MLD) Treatment Market by Company
Takeda
GlaxoSmithKline Plc
RegenxBio Inc
Recursion Pharmaceuticals Inc
ArmaGen Inc
Metachromatic Leukodystrophy (MLD) Treatment Segment by Type
AGT-183
DUOC-01
GSK-2696274
Others
Metachromatic Leukodystrophy (MLD) Treatment Segment by Application
Hospital
Clinic
Others
Metachromatic Leukodystrophy (MLD) Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metachromatic Leukodystrophy (MLD) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Metachromatic Leukodystrophy (MLD) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metachromatic Leukodystrophy (MLD) Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Metachromatic Leukodystrophy (MLD) Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Metachromatic Leukodystrophy (MLD) Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Metachromatic Leukodystrophy (MLD) Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- AGT-183
- DUOC-01
- GSK-2696274
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Takeda
- GlaxoSmithKline Plc
- RegenxBio Inc
- Recursion Pharmaceuticals Inc
- ArmaGen Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size (2021-2032)
- 2.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales (2021-2032)
- 2.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Market Average Price (2021-2032)
- 2.3 Metachromatic Leukodystrophy (MLD) Treatment by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 AGT-183
- 2.3.3 DUOC-01
- 2.3.4 GSK-2696274
- 2.3.5 Others
- 2.4 Metachromatic Leukodystrophy (MLD) Treatment by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue of Manufacturers (2021-2026)
- 3.4 Global Metachromatic Leukodystrophy (MLD) Treatment Average Price by Manufacturers (2021-2026)
- 3.5 Global Metachromatic Leukodystrophy (MLD) Treatment Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Metachromatic Leukodystrophy (MLD) Treatment, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Metachromatic Leukodystrophy (MLD) Treatment, Product Type & Application
- 3.8 Global Manufacturers of Metachromatic Leukodystrophy (MLD) Treatment, Established Date
- 3.9 Global Metachromatic Leukodystrophy (MLD) Treatment Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 GlaxoSmithKline Plc
- 4.2.1 GlaxoSmithKline Plc Company Information
- 4.2.2 GlaxoSmithKline Plc Business Overview
- 4.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
- 4.2.5 GlaxoSmithKline Plc Recent Developments
- 4.3 RegenxBio Inc
- 4.3.1 RegenxBio Inc Company Information
- 4.3.2 RegenxBio Inc Business Overview
- 4.3.3 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
- 4.3.5 RegenxBio Inc Recent Developments
- 4.4 Recursion Pharmaceuticals Inc
- 4.4.1 Recursion Pharmaceuticals Inc Company Information
- 4.4.2 Recursion Pharmaceuticals Inc Business Overview
- 4.4.3 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
- 4.4.5 Recursion Pharmaceuticals Inc Recent Developments
- 4.5 ArmaGen Inc
- 4.5.1 ArmaGen Inc Company Information
- 4.5.2 ArmaGen Inc Business Overview
- 4.5.3 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
- 4.5.5 ArmaGen Inc Recent Developments
5 Global Metachromatic Leukodystrophy (MLD) Treatment Market Scenario by Region
- 5.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region: 2021-2032
- 5.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region: 2021-2026
- 5.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region: 2027-2032
- 5.3 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region: 2021-2032
- 5.3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region: 2021-2026
- 5.3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region: 2027-2032
- 5.4 North America Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Country
- 5.4.1 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2032)
- 5.4.3 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Country
- 5.5.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2032)
- 5.5.3 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Country
- 5.6.1 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Country
- 5.7.1 South America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2032)
- 5.7.3 South America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2032)
- 6.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2021-2032)
- 6.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2021-2032)
- 6.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2021-2032)
- 6.3 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2032)
- 7.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2021-2032)
- 7.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2021-2032)
- 7.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2021-2032)
- 7.3 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Metachromatic Leukodystrophy (MLD) Treatment Value Chain Analysis
- 8.1.1 Metachromatic Leukodystrophy (MLD) Treatment Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Metachromatic Leukodystrophy (MLD) Treatment Production Mode & Process
- 8.2 Metachromatic Leukodystrophy (MLD) Treatment Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Metachromatic Leukodystrophy (MLD) Treatment Distributors
- 8.2.3 Metachromatic Leukodystrophy (MLD) Treatment Customers
9 Global Metachromatic Leukodystrophy (MLD) Treatment Analyzing Market Dynamics
- 9.1 Metachromatic Leukodystrophy (MLD) Treatment Industry Trends
- 9.2 Metachromatic Leukodystrophy (MLD) Treatment Industry Drivers
- 9.3 Metachromatic Leukodystrophy (MLD) Treatment Industry Opportunities and Challenges
- 9.4 Metachromatic Leukodystrophy (MLD) Treatment Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst